Allergan Plc, Research and External Scientific Innovation , Irvine , CA , USA.
Expert Opin Ther Targets. 2019 Sep;23(9):755-771. doi: 10.1080/14728222.2019.1659779. Epub 2019 Sep 1.
: In the past 30 years, only two drugs have received FDA approval for the treatment of androgenetic alopecia reflecting a lack of success in unraveling novel targets for pharmacological intervention. However, as our knowledge of hair biology improves, new signaling pathways and organogenesis processes are being uncovered which have the potential to yield more effective therapeutic modalities. : This review focuses on potential targets for drug development to treat hair loss. The physiological processes underlying the promise of regenerative medicine to recreate new functional hair follicles in bald scalp are also examined. : The discovery of promising new targets may soon enable treatment options that modulate the hair cycle to preserve or extend the growth phase of the hair follicle. These new targets could also be leveraged to stimulate progenitor cells and morphogenic pathways to reactivate miniaturized follicles in bald scalp or to harness the potential of wound healing and embryogenic development as an emerging paradigm to generate new hair follicles in barren skin.
在过去的 30 年中，只有两种药物获得了 FDA 批准用于治疗雄激素性脱发，这反映了在揭示药理学干预的新靶点方面缺乏成功。然而，随着我们对毛发生物学知识的提高，新的信号通路和器官发生过程正在被揭示，这些过程有可能产生更有效的治疗方式。
这篇综述重点介绍了治疗脱发的药物开发的潜在靶点。同时也研究了再生医学在创造光秃头皮上具有新功能的毛囊方面的前景所基于的生理过程。
有希望的新靶点的发现可能很快就能使调节毛发生长周期的治疗选择得以实现，从而维持或延长毛囊的生长阶段。这些新的靶点也可以被利用来刺激祖细胞和形态发生途径，以使光秃头皮上的微型化毛囊重新活跃，或者利用创伤愈合和胚胎发育的潜力，作为一种新兴的范例，在贫瘠的皮肤上产生新的毛囊。
